EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

OMIP‐117: 40‐Parameter/37‐Color Spectral Cytometry Panel for Robust Immunoprofiling of Human Lymphoid Subsets in Cancer Patients

Ondrej Venglar iD, Eva Radova, Lucie Broskevicova, Roman Hajek, Tomas Jelinek iD

Cytometry Part A · 2025

DOI: 10.1002/cyto.a.24962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part A, 2025. Verfasst von Ondrej Venglar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Hauptthemen laut MEDLINE: Flow Cytometry, Neoplasms, Lymphocyte Subsets, Immunophenotyping. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: OP-JAK, LERCO, Agentura Pro Zdravotnický Výzkum České Republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The analysis of immune cell compartments in cancer patients is crucial to predict treatment efficacy and relapse. We introduce a robust 40‐parameter, 37‐channel spectral cytometry panel designed to profile human lymphoid subsets and CAR‐T cell expansion, with the capability to assess exhaustion status by profiling immune checkpoints and activating receptors in cancer patients. Developed for the 5‐laser Cytek Aurora, the panel optimizes fluorophore selection and uses three pairs of mutually exclusive markers assigned to a single fluorescent parameter to simplify setup and ensure robust data, adopting a conservative design choice to keep similarity indices below 0.85; though higher overlaps can still yield high‐quality data when best practices are applied. The panel enables detailed analysis of well‐defined lymphoid subsets using a conventional gating strategy, as well as detection of unconventional subsets with variable expression patterns by unsupervised algorithm‐based analysis. The effectiveness of the panel is demonstrated through a dataset simulating the progression of multiple myeloma, from pre‐malignant disease to a highly aggressive stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Flow CytometryNeoplasmsLymphocyte SubsetsImmunophenotypingMultiple MyelomaHumansAlgorithms

Stichwörter der Autor:innen

activating receptorscancerexhaustionimmune checkpointsinhibitory receptorslymphocyteslymphoid cellsmultiple myelomaphenotypizationspectral cytometry

Autor:innen und Institutionen

  • Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.

ORCID-Profile: Ondrej Venglar, Tomas Jelinek

Förderung

  • OP-JAK
  • LERCO
  • Agentura Pro Zdravotnický Výzkum České Republiky
  • Fakultní Nemocnice Ostrava
  • Ostravská Univerzita v Ostravě
  • Ministry of Education, Youth and Sports of the Czech Republic
  • EHA Physician Research Grant
  • Ministère de l’Éducation, Gouvernement de l’Ontario

Zitieren

APA

Venglar, O., Radova, E., Broskevicova, L., Hajek, R., & Jelinek, T. (2025). OMIP‐117: 40‐Parameter/37‐Color Spectral Cytometry Panel for Robust Immunoprofiling of Human Lymphoid Subsets in Cancer Patients. Cytometry Part A. https://doi.org/10.1002/cyto.a.24962

Vancouver

Venglar O, Radova E, Broskevicova L, Hajek R, Jelinek T. OMIP‐117: 40‐Parameter/37‐Color Spectral Cytometry Panel for Robust Immunoprofiling of Human Lymphoid Subsets in Cancer Patients. Cytometry Part A. 2025. doi:10.1002/cyto.a.24962

BibTeX
@article{Venglar2025,
  author = {Venglar, Ondrej and Radova, Eva and Broskevicova, Lucie and Hajek, Roman and Jelinek, Tomas},
  title = {OMIP‐117: 40‐Parameter/37‐Color Spectral Cytometry Panel for Robust Immunoprofiling of Human Lymphoid Subsets in Cancer Patients},
  journal = {Cytometry Part A},
  year = {2025},
  doi = {10.1002/cyto.a.24962}
}
Kostenlos starten →